Azimuth Capital Investment Management LLC increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 0.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 128,473 shares of the biopharmaceutical company’s stock after purchasing an additional 268 shares during […]
Institutional & Family Asset Management LLC lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 10.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,501 shares of the biopharmaceutical company’s stock after buying an additional 140 shares during the […]
Nordea Investment Management AB lessened its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 1.7% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 738,110 shares of the biopharmaceutical company’s stock after selling 13,003 shares during the period. Nordea Investment Management […]
Silverarc Capital Management LLC Acquires 2,341 Shares of Gilead Sciences, Inc (NASDAQ:GILD) theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Gilead Sciences (NASDAQ:GILD – Free Report) had its target price trimmed by Royal Bank of Canada from $76.00 to $75.00 in a research note published on Wednesday morning, Benzinga reports. The firm currently has a sector perform rating on the biopharmaceutical company’s stock. Other analysts also recently issued reports about the stock. Deutsche Bank Aktiengesellschaft […]